MediGene AG said that the final results of a Phase 2 study of its treatment for pancreatic cancer, EndoTAG-1, showed a median overall survival of up to 9.4 months for patients who were administered the treatment, together with the chemotherapy drug gemcitabine. The median survival for patients receiving gemcitabine alone was 7.2 months.
